AU2003286845A1 - Amyloid plaque formation by glycosaminoglycans - Google Patents

Amyloid plaque formation by glycosaminoglycans

Info

Publication number
AU2003286845A1
AU2003286845A1 AU2003286845A AU2003286845A AU2003286845A1 AU 2003286845 A1 AU2003286845 A1 AU 2003286845A1 AU 2003286845 A AU2003286845 A AU 2003286845A AU 2003286845 A AU2003286845 A AU 2003286845A AU 2003286845 A1 AU2003286845 A1 AU 2003286845A1
Authority
AU
Australia
Prior art keywords
glycosaminoglycans
plaque formation
amyloid plaque
amyloid
formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003286845A
Other versions
AU2003286845A8 (en
Inventor
Gerardo M. Castillo
Paula Y. Choi
Beth P. Nguyen
Virginia J. Sanders
Alan D. Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoTech Inc
Original Assignee
ProteoTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoTech Inc filed Critical ProteoTech Inc
Publication of AU2003286845A8 publication Critical patent/AU2003286845A8/en
Publication of AU2003286845A1 publication Critical patent/AU2003286845A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU2003286845A 2002-11-01 2003-10-31 Amyloid plaque formation by glycosaminoglycans Abandoned AU2003286845A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42318502P 2002-11-01 2002-11-01
US60/423,185 2002-11-01
PCT/US2003/034797 WO2004041779A2 (en) 2002-11-01 2003-10-31 Amyloid plaque formation by glycosaminoglycans

Publications (2)

Publication Number Publication Date
AU2003286845A8 AU2003286845A8 (en) 2004-06-07
AU2003286845A1 true AU2003286845A1 (en) 2004-06-07

Family

ID=32312619

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286845A Abandoned AU2003286845A1 (en) 2002-11-01 2003-10-31 Amyloid plaque formation by glycosaminoglycans

Country Status (5)

Country Link
EP (1) EP1562978A4 (en)
JP (1) JP4469281B2 (en)
AU (1) AU2003286845A1 (en)
CA (1) CA2504035A1 (en)
WO (1) WO2004041779A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888937B1 (en) * 2005-07-21 2012-10-26 Biomerieux Sa METHOD OF DETECTING FCPA USING FCPA AGGREGATION AGENT AND FORM AGGREGATE CAPTURING AGENT
WO2021200940A1 (en) * 2020-03-31 2021-10-07 富士レビオ株式会社 METHOD FOR IMMUNOASSAY OF AMYLOID β IN BLOOD, AND KIT FOR SAME

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610829D0 (en) * 1996-05-23 1996-07-31 Medical Res Council Screening of agents for treatment of azlheimers disease
EP1064013A4 (en) * 1998-03-13 2005-05-11 Univ Washington $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES

Also Published As

Publication number Publication date
JP4469281B2 (en) 2010-05-26
WO2004041779A2 (en) 2004-05-21
AU2003286845A8 (en) 2004-06-07
EP1562978A2 (en) 2005-08-17
JP2006507488A (en) 2006-03-02
CA2504035A1 (en) 2004-05-21
EP1562978A4 (en) 2007-10-10
WO2004041779A3 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
AU2003293632A1 (en) Phenethanolamine derivatives
EP1682493B8 (en) Amidoacetonitrile derivatives
AU2003211362A1 (en) N-hydroxycarboxamide derivative
EP1606277B8 (en) Imidazol-4-yl-ethynyl-pyridine derivatives
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003227189A1 (en) Cleansing preparation
AU2003238043A1 (en) Substituted imidazotriazines
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003241035A1 (en) Counter
AU2003252722A1 (en) Toothbrush
AU2003297630A1 (en) Photo-imageable nanocomposites
AU2003303648A1 (en) Novel 5-hydroxyindole-3-carboxylate derivatives
EP1706373B8 (en) Amidoacetonitrile derivatives
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2003286845A1 (en) Amyloid plaque formation by glycosaminoglycans
AU2003277632A1 (en) Toothbrush
AU2003903325A0 (en) Chewable dental product
AU2003238180A1 (en) 2-naphtamide derivatives
AU2003273398A1 (en) Aroyl-piperidine derivatives
AU2002249639A1 (en) Pyranocoumarin derivatives
AU2002258241A1 (en) Toothbrush
AU2003288012A1 (en) Isothiazolyl-benzoxazine derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase